DOCSLIB.ORG

Annual Report 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2017 Annual Report 2 017 Augmented Version Bayer Annual Report 2017 The integrated Bayer Annual Report 2017 is available in a print version and in an aug- mented online version (Annual Report 2017 – Augmented Version). The online version contains the notes to the consolidated financial state- ments of the Bayer Group, along with additional information on the management report. The Annual Report 2017 – Augmented Version can be found at www.bayer.com/AR17. Cover photo: Farmer Aaron Gingerich with his daughter Kylie on one of his cornfields in Illinois, United States. You can read more in the Magazine section, which starts on page 8. At a Glance Sales EBITDA Net Income Before Special Items 1 2 +1.5% -0.3 % + 61.9% 2016 2017 Core Earnings per Share Supplier Management Investment in Research and Development 2 +1.0 % 99.5% of all strategically important suppliers billion evaluated since 2012 €4.5 Proportion of Women Specific Greenhouse Gas Emissions3 Energy Efficiency3 in Senior Management 2 - % up by 4.5 2 % 3.8% 32 1 Currency- and portfolio-adjusted 2 Changes from 2016; 2016 figures restated 3 Bayer excluding Currenta Fiscal 2017 Bayer: business at prior-year levelFiscal 2017 – on track with strategy Bayer:Group sales business €35.0 billion (Fx at & portfolioprior-year adj. + 1.5%) levelAnother – recordon trackyear for Pharmaceuticals with strategy Weak business development at Consumer Health CrGropoup Science sales €35.0 business billion down (Fx &against portfolio prior adj. year + 1.5%) due to situation in Brazil – measures taking effect Another record year for Pharmaceuticals EBITDA before special items €9.3 billion (– 0.3%) Weak business development at Consumer Health Net income €7.3 billion (+ 61.9%) Crop Science business down against prior year due to Coresituation earnings in Brazil per –share measures €6.74 taking(+1.0% effect) CovestroEBITDA before deconsolidated special items – additional €9.3 billion cash (– 0.3%) inflows of €4.7 billion Net income €7.3 billion (+ 61.9%) Monsanto acquisition expected to close in Core earnings per share €6.74 (+ 1.0%) second quarter of 2018 Covestro deconsolidated – additional cash Further progress in implementing sustainability targets inflows of €4.7 billion Group outlook for 2018: increase in sales (Fx & portfolio Monsanto acquisition expected to close in adj.), EBITDA before special items and core earnings per second quarter of 2018 share at prior-year level due to currency effects Further progress in implementing sustainability targets Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects Key Data Change from € million 2016 2017 2016 (%) Bayer Group Sales 34,943 35,015 + 0.2% 1 EBITDA 8,801 8,563 – 2.7% 1 EBITDA before special items 9,318 9,288 – 0.3% 1 EBITDA margin before special items 26.7% 26.5% 1 EBIT 5,738 5,903 + 2.9% 1 EBIT before special items 6,826 7,130 + 4.5% Income before income taxes 4,773 4,577 – 4.1% Net income (from continuing and discontinued operations) 4,531 7,336 + 61.9% 1 Earnings per share (from continuing and discontinued operations) (€) 5.44 8.41 + 54.6% 1 Core earnings per share (from continuing operations) (€) 6.67 6.74 + 1.0% Net cash provided by operating activities (from continuing and discontinued operations) 9,089 8,134 – 10.5% Net financial debt 11,778 3,595 – 69.5% 2 Capital expenditures as per segment table 2,627 2,418 – 8.0% Bayer AG Total dividend payment 2,233 2,315 + 3.7% Dividend per share (€) 2.70 2.80 + 3.7% Innovation Research and development expenses 4,405 4,504 + 2.2% Ratio of R&D expenses to sales – Pharmaceuticals (%) 16.7 16.2 Ratio of R&D expenses to sales – Crop Science (%) 11.7 11.7 Employees in research and development 14,213 14,041 – 1.2% Employees 3 Number of employees (Dec. 31) 99,592 99,820 + 0.2% Personnel expenses (including pension expenses) (€ million) 9,459 9,528 + 0.7% Proportion of women in senior management (%) 31 32 Proportion of employees with health insurance (%) 98 98 Fluctuation (voluntary / total) (%) 4.8 / 13.2 4.8 / 10.4 Hours of vocational and ongoing training per employee 23.0 23.4 + 1.7% Safety & Environmental Protection Recordable Incident Rate (RIR) for Bayer employees 0.40 0.45 + 12.5% 4 Loss of Primary Containment Incident Rate (LoPC-IR) 0.17 0.13 – 21.4% Total energy consumption (terajoules) 26,243 25,832 – 1.6% 5 Energy efficiency (kWh / €1,000 external sales) 130 125 – 3.8% 6 Total greenhouse gas emissions (CO2 equivalents in million t) 4.64 3.63 – 21.8% Specific greenhouse gas emissions (kg CO2 equivalents / €1,000 external sales) 7 according to the market-based method 48.45 46.26 – 4.5% Water use (million m³) 93 98 + 6.0% 2016 figures restated 1 For definitions of the indicators see A 2.4 2 Group total 2016 including Covestro 3 Employees calculated as full-time equivalents (FTEs) 4 Number of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours 5 Quotient of total energy consumption and manufactured sales volume; Bayer excluding Currenta 6 Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and cooling (according to the market-based method); portfolio-adjusted in accordance with the GHG Protocol 7 Bayer excluding Currenta Chairman’s Letter People should know what Bayer stands for I am pleased to present to you Bayer’s new annual report. It reflects an eventful year in which our employees around the world once again showed great commitment to drive the success of our company. On behalf of the Board of Management – and on your behalf as well I’m sure – I would like to sincerely thank all our employees for their dedication. The trust you have in our employees, in the members of the Supervisory Board and Board of Management, and in me personally strengthens us in our daily work. I would like to sincerely thank you and I am pleased that we are once again able to let you participate in Bayer’s success. We are therefore proposing to the Annual Stockholders’ Meeting an increase in the dividend to €2.80 per share. 2017 was a year of ups and downs. We saw many advances, but also experienced setbacks. We received new approvals, formed new collabo- rations and celebrated encouraging successes. But we also had to deal with unexpectedly high inventories in our Crop Science Division in Brazil and with the weak business development of our Consumer Health Divi- sion, which meant we had to adjust our guidance during the year. Overall, sales and earnings in 2017 remained only on a par with 2016. 2 Chairman’s Letter Bayer Annual Report 2017 Augmented Version Our share price reflected this development. Over the course of 2017, Bayer stock delivered just over seven percent, which was less than the DAX and the Euro STOXX 50. The ongoing regulatory process for the planned Monsanto acquisition certainly played a role here. We are very confident that we will receive final antitrust approval in the second quarter of 2018. In 2017, we also benefited from the long-term realignment of our company across the rest of the portfolio. Since the IPO of Covestro in October 2015, we have been aiming to sell our shares step by step and to achieve full sepa- ration from Covestro in the medium term. Last year, Bayer AG reduced its direct interest in Covestro from 64.2 percent to 24.6 percent, generating cash inflows of around €4.7 billion thanks to Covestro’s good share price perfor- mance. Bayer’s strategic foresight has proved successful and we also have had a lucky hand. It is with the same long-term perspective that we are pursuing the Monsanto acquisition. We are deeply convinced that both companies together can create significant additional value for our customers and shareholders, as well as for the society in which we live and whose acceptance we need. Providing food in high quality, sufficient quantity and at affordable prices is crucial to human coexistence. And we want to contribute to that. In 2017, we made important progress in obtaining antitrust approval for the planned acquisition. Of particular importance was the agreement with BASF in October regarding large parts of our seeds business and the Liberty™ / LibertyLink™ herbicide platform. These are excellent businesses that have been built up by our employees over the years. We regret having to divest these businesses, but we are convinced that in BASF we have found a long- term strategic purchaser and an employer with a first-class reputation. Bayer reached another long-term decision in November by in-licensing two development candidates from biotechnology company Loxo Oncology. Both these candidates complement our existing oncology portfolio. Moreover, it shows that we are keeping our word because we have always emphasized that we will continue to invest in our other businesses regardless of the acquisition of Monsanto. Bayer Annual Report 2017 Chairman’s Letter 3 Augmented Version Covestro, Monsanto and Loxo are prime examples of how Bayer has demon- strated its strategic foresight in 2017. Clear focus and long-term perspective – that’s the way we run our company. We have aligned our business activities to the main societal challenges in the fields of health and nutrition, and we are convinced that we are able to provide substantial and sustainable solutions, based on the highest standards and our responsibility to humankind and the environment.
Load more

Recommended publications
  • Grundstücksmarktbericht 2020 Für Den Kreis Mettmann
    Der Gutachterausschuss für Grundstückswerte im Kreis Mettmann HEILIGENHAUS VELBERT RATINGEN WÜLFRATH METTMANN ERKRATH HAAN HILDEN LANGENFELD (RHLD.) MONHEIM AM RHEIN Grundstücksmarktbericht 2020 für den Kreis Mettmann www.boris.nrw.de Der Gutachterausschuss für Grundstückswerte im Kreis Mettmann Grundstücksmarktbericht 2020 Berichtszeitraum 16.11.2018 – 15.11.2019 Übersicht über den Grundstücksmarkt im Kreis Mettmann Mettmann, im Mai 2020 Fotos Titelseite: 1 Erkrath, Eisenbahnbrücke Bergische Allee 2 Langenfeld, Wasserburg Haus Graven 3 Monheim am Rhein, Aalschokker 4 Mettmann, Freiheitsstraße Schäfergruppe 5 Mettmann, Verwaltungsgebäude II, GAA 6 Hilden, Eisengasse mit Reformationskirche 7 Wülfrath, Blick auf Düssel 8 Haan, Blick auf Gruiten Dorf 9 Heiligenhaus, Waggonbrücke, Bahnhofstraße Herausgeber Der Gutachterausschuss für Grundstückswerte im Kreis Mettmann Geschäftsstelle Straße Nr. Goethestraße 23 PLZ Ort 40822 Mettmann Telefon 02104 / 99 25 36 Fax 02104 / 99 54 52 E-Mail [email protected] Internet gutachterausschuss.kreis-mettmann.de Gebühr Das Dokument kann unter www.boris.nrw.de gebührenfrei heruntergeladen werden. Bei einer Bereitstellung des Do- kuments oder eines gedruckten Exemplars durch die Geschäftsstelle des Gutachterausschusses beträgt die Gebühr 46 EUR je Exemplar (Nr. 5.3.2.2 des Kostentarifs der Kostenordnung für das amtliche Vermessungswesen und die amtliche Grundstückswertermittlung in Nordrhein-Westfalen). Bildnachweis Geschäftsstelle Lizenz Für die bereitgestellten Daten im Grundstücksmarktbericht
    [Show full text]
  • MON 87708 × MON 89788 × A5547-127 Soybean Xtendflex® Soybeans Herbicide-Tolerant
    MON 87708 × MON 89788 × A5547-127 soybean XtendFlex® soybeans Herbicide-tolerant Key facts Bayer Agriculture BV October 2020 XtendFlex® is a trademark of Bayer Group. Soybean, a key crop MON 87708 × MON 89788 × A5547-127 as well as the genetically modified parental soybean events Soybean (Glycine max) is a high-protein legume MON 87708 and MON 89788 have been developed by grown mainly as food for humans and livestock. It is Monsanto Company, now Bayer CropScience LP, one of the highest natural source of dietary fibre whereas the genetically modified parental soybean (Dhingra et al., 2012). Nine essential amino acids event A5547-127 is owned by BASF Agriculture are found in soybeans, which are necessary for Solutions Seed US LLC. human nutrition and are not produced naturally in the body (Tessari et al., 2016). This crop is also used More information on the parental events can be in industrial products including oils, soaps, found on the European Association for Bioindustries cosmetics, resins, plastics, inks, solvents, and (EuropaBio) website6. biodiesel. Worldwide plantings and regulatory status of The first record of domesticated soybean dates back MON 87708 × MON 89788 × A5547-127 to the 11th century BC in the eastern half of China where it was grown as food. Soybean was cultivated In 2018, approximately 191.7 million hectares of for the first time in Europe in the early 1700's and in genetically modified (GM) crops were grown North America in the early 1800's. worldwide7. In the case of biotech soybean, it continued to be the principal biotech crop in 2018, In 2019-2020, approximately 337.1 million metric occupying 95.9 million hectares.
    [Show full text]
  • Association of Accredited Lobbyists to the European Parliament
    ASSOCIATION OF ACCREDITED LOBBYISTS TO THE EUROPEAN PARLIAMENT OVERVIEW OF EUROPEAN PARLIAMENT FORUMS AALEP Secretariat Date: October 2007 Avenue Milcamps 19 B-1030 Brussels Tel: 32 2 735 93 39 E-mail: [email protected] Website: www.lobby-network.eu TABLE OF CONTENTS Introduction………………………………………………………………..3 Executive Summary……………………………………………………….4-7 1. European Energy Forum (EEF)………………………………………..8-16 2. European Internet Forum (EIF)………………………………………..17-27 3. European Parliament Ceramics Forum (EPCF………………………...28-29 4. European Parliamentary Financial Services Forum (EPFSF)…………30-36 5. European Parliament Life Sciences Circle (ELSC)……………………37 6. Forum for Automobile and Society (FAS)…………………………….38-43 7. Forum for the Future of Nuclear Energy (FFNE)……………………..44 8. Forum in the European Parliament for Construction (FOCOPE)……..45-46 9. Pharmaceutical Forum…………………………………………………48-60 10.The Kangaroo Group…………………………………………………..61-70 11.Transatlantic Policy Network (TPN)…………………………………..71-79 Conclusions………………………………………………………………..80 Index of Listed Companies………………………………………………..81-90 Index of Listed MEPs……………………………………………………..91-96 Most Active MEPs participating in Business Forums…………………….97 2 INTRODUCTION Businessmen long for certainty. They long to know what the decision-makers are thinking, so they can plan ahead. They yearn to be in the loop, to have the drop on things. It is the genius of the lobbyists and the consultants to understand this need, and to satisfy it in the most imaginative way. Business forums are vehicles for forging links and maintain a dialogue with business, industrial and trade organisations. They allow the discussions of general and pre-legislative issues in a different context from lobbying contacts about specific matters. They provide an opportunity to get Members of the European Parliament and other decision-makers from the European institutions together with various business sectors.
    [Show full text]
  • List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company
    List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Algeria Bayer Algerie S.P.A. Argentina Bayer S.A. Argentina Biagro S.A. Argentina Monsanto Argentina SRL Australia Bayer Australia Limited Australia Bayer CropScience Holdings Pty Ltd Australia Bayer CropScience Pty Limited Australia Cotton Growers Services Pty. Limited Australia Imaxeon Pty. Ltd. Australia Monsanto Australia Pty Ltd Bangladesh Bayer CropScience Ltd. Belgium Bayer Agriculture BVBA Belgium Bayer CropScience NV Belgium Bayer NV Bermuda MonSure Limited Bolivia Bayer Boliviana Ltda Bolivia Monsanto Bolivia S.A. Bosnia & Herzeg. Bayer d.o.o. Sarajevo Brazil Alkagro do Brasil Ltda Brazil Bayer S.A. Brazil D&PL Brasil Ltda Brazil Monsanto do Brasil Ltda. Brazil Rede Agro Fidelidade e Intermediacao S.A. Brazil Schering do Brasil Química e Farmacêutica Ltda. Brazil Stoneville Brasil Ltda. Bulgaria Bayer Bulgaria EOOD Burkina Faso Monsanto Burkina Faso SARL Chile Bayer Finance & Portfolio Management S.A. Chile Bayer Finance Ltda. Chile Bayer S.A. Chile Monsanto Chile, S.A. Costa Rica Bayer Business Services Costa Rica, SRL Costa Rica Bayer Medical S.R.L. Costa Rica Bayer S.A. Curacao Pianosa B.V. Germany Adverio Pharma GmbH - 1 - List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Germany AgrEvo Verwaltungsgesellschaft mbH Germany Alcafleu Management GmbH & Co. KG Germany BGI Deutschland GmbH Germany Bayer 04 Immobilien GmbH Germany Bayer 04 Leverkusen Fußball GmbH Germany Bayer 04 Leverkusen
    [Show full text]
  • Rede Israel-Viertel
    Dear Ladies and Gentlemen, dear Mr. Ambassador, dear friends from Tirat Carmel, Shalom and welcome to Monheim’s Israeli quarter. I am delighted to have you here to participate and share in today’s inauguration ceremony. Thank you all for coming. I’d like to express my deepest appreciation for the fact that His Excellency Mr. Jeremy Issacharoff, the Ambassador of Israel, is with us today. Let me offer you, Mr. Ambassador, on behalf of all those who are present here, our most grateful welcome. It's my pleasure to extend a warm welcome to my friend, Mr. Arie Tal, the mayor of Tirat Carmel. I am glad to have you here together with Mr. Shmulik Katoni, the city director of Tirat Carmel, Mr. Shlomo Dahan, head of Tirat Carmel’s department of education, and Mr. Boris Tikman, manager of urban planning in Tirat Carmel. I’d like to welcome furthermore the former president of the state parliament of North Rhine Westphalia and honorary mayor of Monheim am Rhein Mrs Ingeborg Friebe, the administrative head of the district of Mettmann, Mr. Thomas Hendele, the former mayor of Monheim, Mr. Hans-Dieter Kursawe, and Mr. Hagen Bastian, the headmaster of Otto-Hahn- Gymnasium and chairman of Monheim’s German-Israeli friendship association. Today, after 31 years of exchange between Tirat Carmel and Monheim am Rhein, we want to make another step forward in strengthening our friendship. One and a half years ago, the city council of Monheim has decided (without a single vote against) to name the five new streets in this area after Tirat Carmel and four Jewish or Israeli personalities.
    [Show full text]
  • Market Data from Deutsche Börse
    Market Data + Services Market data from Deutsche Börse Real-time. Reliable. Relevant. Deutsche Börse is a global German company Providing access to international capital markets Market data from Deutsche Börse 3 Deutsche Börse Group A global market operator Deutsche Börse Group, whose history dates back to 1585, is today one of the largest exchange organisations world-wide. The Group is headquartered in Germany and has more than 4,000 employees working to provide investors, financial institutions and companies access to global capital markets. Deutsche Börse Group’s integrated business model covers the entire process chain from securities and derivatives trading, clearing, settlement and custody, through to market data and the development and operation of electronic trading systems. Deutsche Börse Group owns the derivatives trading venue Eurex Exchange, as well as the settlement and custody business Clearstream. The Group’s market data business, operated by Market Data + Services, is trusted by more than 2,500 institutions and 160,000 subscribers. Deutsche Börse Group’s business areas Deutsche Börse Group Eurex Xetra Clearstream Market Data + Exchange Services Cash Settlement, market trading financing services Derivatives Information, indices, market trading tools, market solutions Simplified illustration Trademarks AlphaFlash ®, CEF ®, DAX ®, Eurex ® and Xetra ® are registered trademarks of Deutsche Börse AG. STOXX ® and EURO STOXX 50 ® are registered trademarks of STOXX Limited. Information is the basis for successful decision making
    [Show full text]
  • Allianz SE File No
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ' DIVISION OF MARKET REGULATION March 23,2007 Nikolaos G. Andronikos, Esq. Sullivan & Cromwell LLP 125 Broad Street New York, NY 10004 Re: Allianz SE File No. TP 07-51 Dear Mr. Andronikos: In your letter dated March 23,2007, as supplemented by conversations with the staff, you request on behalf of Allianz SE ("Allianz") an exemption fiom Rule 102 of Regulation M under the Securities Exchange Act of 1934 ("Exchange Act") in connection with the exchange offer ("Offer") being conducted by Allianz and its wholly-owned subsidiary, Allianz Holding France SAS, for all outstanding shares ("AGF Shares") in Assurances Gknkrales de France ("AGF") that they do not already own. Pursuant to the Offer, AGF shareholders will have the right to exchange their AGF Shares for a fixed sum of cash and shares of Allianz ("Allianz Shares"). You seek an exemption to permit Dresdner Bank AG ("Dresdner Bank"), a separate subsidiary of Allianz, to conduct specified transactions outside the United States in Allianz Shares during the distribution of Allianz Shares represented by the Offer. Specifically, you request that Dresdner Bank be permitted to continue to engage in market-making, derivatives market-making and hedging, and unsolicited brokerage activities as described in your letter.' You also seek an exemption to permit Dresdner Kleinwort Securities LLC ("Dresdner Kleinwort Securities"), Dresdner Bank's affiliated U.S. broker-dealer, to engage in unsolicited brokerage activities as described in your letter. We have attached a copy of your correspondence to avoid reciting the facts set forth therein.
    [Show full text]
  • Steven Sanders, Et Al. V. Bayer (AG) Aktiengesellschaft, Et Al. 03-CV-1546-Second Consolidated Amended Complaint
    Q,^.IGiNAL &&,iN 2i 4- L UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -_DOF x Consolidated Civil Action IN RE BAYER AG SECURITIES No. 03 CV 1546 (WHP) LITIGATION Class Action x 71 :n = SECOND CONSOLIDATED AMENDED COMPLAINT Jury Trial Demand MILBERG WEISS BERSHAD & SCHULMAN LLP Melvyn I. Weiss (MW-1392) Michael C . Spencer (MS-8874) Lee A. Weiss (LW-1130) Jennifer Sclar (JS-7313) One Pennsylvania Plaza New York, NY 10119 (212) 594-5300 Attorneys for Lead Plaintiff January 14, 2005 i • ' Table of Contents Page SUMMARY OF CLAIMS ...............................................................................................................2 JURISDICTION AND VENUE ...................................................................................................... 8 A. General Jurisdiction and Venue ............................................................................... 8 B. Subject Matter Jurisdiction Over Claims of Foreign Purchasers on Foreign Exchanges ................................................................................................................ 8 PARTIES .......................................................................................................................................12 RELEVANT EVENTS ..................................................................................................................14 A. Background of the Statin Market ...........................................................................14 B. FDA Approval and Introduction of Baycol; Early Safety Warnings
    [Show full text]
  • Europabio Position on Advanced Therapy Medicinal Products* March 2013
    EuropaBio Position on Advanced Therapy Medicinal Products* March 2013 Table of Contents 1 Introduction .................................................................................................................... 1 2 Overall assessment of Regulation EC/1394/2007 .......................................................... 2 2.1 Difficulties inherent to the requirements of the Regulation and its implementation at European level ..................................................................................... 2 2.2 Discrepancies in the national implementation of some of the ATMP Regulation requirements ................................................................................................... 3 2.2.1 The specific issue of Hospital Exemption: ....................................................... 4 2.2.2 Biobanks, Access to Tissue & Cells & the Tissue & Cells Directive ................ 5 2.3 HTA Requirements ................................................................................................. 5 2.4 SME and Development Incentives .......................................................................... 6 3 Recommandations and Conclusion ............................................................................... 6 1 Introduction Further to the European Commission’s invitation to EuropaBio to provide input regarding the implementation of the Advanced Therapy Medicinal Products (ATMP) Regulation (EC/1394/2007) (“the Regulation”) as part of a wider Commission analysis on the Regulation, EuropaBio conducted a
    [Show full text]
  • Science for a Better Life
    Financial Calendar Bayer Group Bayer Sustainable Development Report 2005 Bayer Sustainable Development Report 2005 Science For A Better Life Sustainable Development Report 2005 2005 q2 2006 Interim Report Tuesday, August 1, 2006* Sustainable Development Report 2005 This year’s Sustainable Development Report is also the first to depict the relevant information q3 2006 Interim Report for Bayer AG in its new structure – without Lanxess AG. It continues our Group’s long tradition Tuesday, October 31, 2006* of environmental and sustainability reporting that began with the publishing of our first report with economic, social and environmental data in 1976. Annual Stockholders’ Meeting 2007 Friday, April 27, 2007 * In the event of the successful acquisition of Schering AG, Reporting objectives and method lists the pages on which the Report provides infor- Payment of Dividend publication of the q2 and q3 2006 interim reports will be Like our previous reports, the Sustainable Develop- mation on the individual gri indicators. The state- Monday, April 30, 2007 deferred to later dates, which will be posted on the Internet ment Report 2005 is designed to give an insight ments provided here apply to all sites and activities at www.investor.bayer.com. into our commitment to sustainable development of the Bayer Group. Our environmental and safety Rahima Indira Hanifa, and is aimed primarily at stockholders, business data cover companies in which we have a share Indonesia, in front of Group Report Development Sustainable partners, employees and the media. However, the of more than 51 percent. A worldwide recording headquarters in Leverkusen publication also addresses non-governmental or- system is being established for some social per- Global commitment to the environment, education, sports and health ganizations, suppliers and authorities with whom formance indicators.
    [Show full text]
  • 2019 Breakthrough Summit Co-Host Committee 2019 Breakthrough
    2019 Breakthrough Summit Co-Host Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Patents, Royalties, Travel, Speakers' Expert Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Research Funding Other Intellectual Accommodations, Other Bureau Testimony Interests Property Expenses Dae Ho Lee Abbvie, AstraZeneca/MedImmune, Boehringer ST Cube Ingelheim, Bristol-Myers Squibb, Chong Kun Dang Pharmaceutical, CJ Healthcare, Janssen, Lilly, Merck, MSD, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Samyang, ST Cube, Takeda Ekaphop Amgen, AstraZeneca, Boehringer Ingelheim, Bristol- AstraZeneca, MSD, Sirachainan Myers Squibb, Diethelm Keller Logistics, LF Asia, Pfizer Merck, MSD, Mundipharma, Roche, Sanofi/Aventis Lillian L. Siu Agios (I) Agios (I) AstraZeneca/MedImmune, Loxo, Merck, Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), MorphoSys, Roche, Symphony Evolution Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), MedImmune (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Symphony Evolution (Inst) Virote Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Lilly, Amgen, AstraZeneca, Sriuranpong Bristol-Myers Squibb, Eisai, Lilly, MSD Oncology, Eisai, MSD Oncology, Novartis, Roche MSD Oncology,
    [Show full text]
  • Notes to the Consolidated Financial Statements of the Bayer Group
    Five-Year Summary Bayer Annual Report 2018 Five-Year Summary 2014 2015 2016 2017 2018 Bayer Group (€ million) Sales 41,339 46,085 34,943 35,015 39,586 EBITDA1 8,315 9,573 8,801 8,563 10,266 1 EBITDA before special items 8,685 10,256 9,318 9,288 9,547 1 EBITDA margin before special items (in %) 21.0 22.3 26.7 26.5 24.1 EBIT1 5,395 6,241 5,738 5,903 3,914 1 EBIT before special items 5,833 7,060 6,826 7,130 6,480 Income before income taxes 4,414 5,236 4,773 4,577 2,318 Net income (from continuing and discontinued operations) 3,426 4,110 4,531 7,336 1,695 1 Earnings per share (from continuing and discontinued operations) (€) 4.14 4.97 5.44 8.29 1.80 1 Core earnings per share (from continuing operations) (€) 5.89 6.82 6.67 6.64 5.94 Net cash provided by operating activities (from continuing and discontinued operations) 5,810 6,890 9,089 8,134 7,917 Net financial debt 19,612 17,449 11,778 3,595 35,679 2 Capital expenditures (as per segment table) 2,484 2,554 2,627 2,418 2,564 Bayer AG Total dividend payment 1,861 2,067 2,233 2,402 2,611 Dividend per share (€) 2.25 2.50 2.70 2.80 2.80 Innovation Research and development expenses (€ million) 3,537 4,274 4,405 4,504 5,246 Ratio of R&D expenses to sales – Pharmaceuticals (%) 15.6 16.0 16.7 16.2 15.5 Ratio of R&D expenses to sales – Crop Science (%) 10.3 10.7 11.7 11.7 13.0 Employees in research and development3 13,900 14,753 14,213 14,041 17,275 Employees 3 Number of employees (Dec.
    [Show full text]